AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) and RedHill Biopharma Ltd. (NASDAQ:RDHL) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AVEO Pharmaceuticals Inc.||5.41M||14.91||5.33M||-0.20||0.00|
|RedHill Biopharma Ltd.||8.36M||29.30||38.82M||-1.70||0.00|
Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 hightlights the net margins, return on assets and return on equity of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|AVEO Pharmaceuticals Inc.||-98.52%||48.1%||-69.9%|
|RedHill Biopharma Ltd.||-464.35%||0%||0%|
The table delivered features the ratings and recommendations for AVEO Pharmaceuticals Inc. and RedHill Biopharma Ltd.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|AVEO Pharmaceuticals Inc.||0||2||1||2.33|
|RedHill Biopharma Ltd.||0||0||2||3.00|
AVEO Pharmaceuticals Inc. has a 244.77% upside potential and an average price target of $2. On the other hand, RedHill Biopharma Ltd.’s potential upside is 88.36% and its average price target is $16.5. The results provided earlier shows that AVEO Pharmaceuticals Inc. appears more favorable than RedHill Biopharma Ltd., based on analyst belief.
Institutional and Insider Ownership
Roughly 41.9% of AVEO Pharmaceuticals Inc. shares are owned by institutional investors while 29.11% of RedHill Biopharma Ltd. are owned by institutional investors. Insiders owned roughly 0.3% of AVEO Pharmaceuticals Inc.’s shares. Competitively, 19.1% are RedHill Biopharma Ltd.’s share owned by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|AVEO Pharmaceuticals Inc.||-15.19%||-19.85%||-72.92%||-80.67%||-80.4%||-64.96%|
|RedHill Biopharma Ltd.||-1.67%||-7.59%||-6.35%||2.68%||19.47%||38.2%|
For the past year AVEO Pharmaceuticals Inc. had bearish trend while RedHill Biopharma Ltd. had bullish trend.
On 7 of the 12 factors AVEO Pharmaceuticals Inc. beats RedHill Biopharma Ltd.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. VincentÂ’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. Its clinical-stage pipeline includes TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two European Union member states under the European Decentralized Procedure. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.